References
Capdeville R, Silberman S. Imatinib: a targeted clinical drug development. Semin Hematol. 2003;40:15–20.
Deininger MW, O’Brien SG, Ford JM, Druker BJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol. 2003;21:1637–47.
Pardanani A, Reeder T, Porrata LF, Li C, Tazelaar HD, Baxter EJ, Witzig TE, Cross NCP, Tefferi A. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood. 2003;101:3391–7.
Tefferi A. Modern diagnosis and treatment of primary eosinophilia. Acta Haematol. 2005;114:52–60.
Gotlib J. Molecular classification and pathogenesis of eosinophilic disorders: 2005 update. Acta Haematol. 2005;114:7–25.
Pardanani A, Brockman SR, Paternoster SF, Flynn HC, Ketterling RP, Lasho TL, Ho C, Li C, Dewald GW, Tefferi A. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood. 2004;104:3038–45.
Walsh GM. Eosinophil granule proteins and their role in disease. Curr Opin Hematol. 2001;8:28–33.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Sato, E., Sugimoto, K., Hamano, Y. et al. Multiple brain infarctions induced by imatinib mesylate in a patient with clonal eosinophilia. Int J Hematol 87, 444–445 (2008). https://doi.org/10.1007/s12185-008-0074-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12185-008-0074-7